Osimertinib-Induced Cardiomyopathy

Osimertinib-Induced Cardiomyopathy

Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib...

Full description

Bibliographic Details
Main Authors: Shruti R. Patel, MD, Sherry-Ann N. Brown, MD, PhD, Jilan E. Kubusek, PharmD, RPh, Aaron S. Mansfield, MD, Narjust Duma, MD
Format: Article
Language:English
Published: Elsevier 2020-04-01
Series:JACC: Case Reports
Subjects:
cardiotoxicity
cardio-oncology
heart failure
osimertinib
reduced ejection fraction
Online Access:http://www.sciencedirect.com/science/article/pii/S2666084920300395

Internet

http://www.sciencedirect.com/science/article/pii/S2666084920300395

Similar Items